Nektar releases promising phase 2 results for NKTR-255 in lymphopenia
seekingalpha
2024-11-08
PALMIHELP/iStock via Getty Images
Nektar Therapeutics (NASDAQ:NKTR) said that interim data from a phase 2 trial showed that a combination of NKTR-255 with AstraZeneca's (AZN) Imfinzi (durvalumab) led to reversed radiation induced lymphopenia in patients with locally advanced non-small cell lung cancer receiving